Ebola-Virus- und Marburg-Viruserkrankung

Was ist neu?

Ebola-Viruserkrankung Während der durch die Zaire-Virusvariante hervorgerufenen Ebola-Ausbrüche wurden klinische Studien mit Impfstoffen sowie antiviralen Substanzen durchgeführt. Aktuell stehen als Therapie die monoklonalen Antikörper Atoltivimab/Maftivimab/Odesivimab (kombiniert in Inmazeb) und Ansuvimab (Ebanga) zur Verfügung. Zur präventiven Impfung und zur Prä- und Postexpositionsprophylaxe einer Ebola-Virusinfektion (Variante Zaire) sind die Ebola-Zaire-Impfstoffe rVSVΔG-ZEBOV-GP, lebend (Ervebo), Ebola-Zaire-Impfstoff Ad26.ZEBOV-GP, rekombinant (Zabdeno) und der Ebola-Impfstoff (MVA-BN-Filo, rekombinant (Mvabea) geeignet.

Marburg-Viruserkrankung Es gibt derzeit kein zugelassenes Medikament zur Behandlung der Marburg-Viruserkrankung. Trotz erheblicher logistischer Schwierigkeiten und der Tatsache, dass die meisten Marburg-Ausbrüche eher zu klein waren, um Impfstoffstudien zu ermöglichen, wurden von der WHO 3 Impfstoffkandidaten für eine mögliche Studie favorisiert.

Abstract

Viral hemorrhagic fevers (VHF) are serious, often fatal diseases that affect humans and non-human primates. The nomenclature of these diseases has changed in that they are now referred to as viral diseases because the previously named symptoms of fever or hemorrhages are not obligatory. In this article, the focus will be on the VHFs Ebola and Marburg viral disease with the potential for human-to-human transmission; these diseases are so-called high-consequence infectious diseases (HCID), some with considerable potential for epidemic spread and the risk of nosocomial transmission.

Schlüsselwörter

Ebolavirus - Marburgvirus - Impfung

Keywords

ebola virus - marburg virus - vaccine

Publication History

Article published online:
02 November 2023

• Literatur

• 1 Feldmann H, Sprecher A, Geisbert TW. Ebola. N Engl J Med 2020; 382: 1832-1842 DOI: 10.1056/NEJMra1901594.. (PMID: 32441897)
• 2 Mulangu S, Dodd LE, Davey Jr RT. et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 2019; 381: 2293-2303 DOI: 10.1056/NEJMoa1910993. (PMID: 31774950)
• 3 Ständiger Arbeitskreis der Kompetenz- und Behandlungszentren für Krankheiten durch hochpathogene Erreger (STAKOB) beim Robert Koch-Institut (Januar 2023): Hinweise zu Therapie und Prophylaxe von Ebolafieber. Accessed September 27, 2023 at: https://www.rki.de/DE/Content/Kommissionen/Stakob/Stellungnahmen/Therapiehinweise_Ebola.pdf?__blob=publicationFile
• 4 Markham A. REGN-EB3: first approval. Drugs 2021; 81: 175-178 DOI: 10.1007/s40265-020-01452-3. (PMID: 33432551)
• 5 Lee A. Ansuvimab: first approval. Drugs 2021; 81: 595-598 DOI: 10.1007/s40265-021-01483-4. (PMID: 33751449)
• 6 Europeen Medicines Agency. Ervebo Authorisation. (4.8.2022). Accessed September 27, 2023 at: https://www.ema.europa.eu/en/medicines/human/EPAR/ervebo
• 7 Centers for Disease Control and Prevention. Marburg Virus Disease Outbreaks (9.6.2023). Accessed September 27, 2023 at: https://www.cdc.gov/vhf/marburg/outbreaks/chronology.html
• 8 Pigott DM, Golding N, Mylne A. et al. Mapping the zoonotic niche of Marburg virus disease in Africa. Trans R Soc Trop Med Hyg 2015; 109: 366-378 DOI: 10.1093/trstmh/trv024. (PMID: 25820266)
• 9 World Health Organisation. Equatorial Guinea confirms first-ever Marburg virus disease outbreak (13.2.2023). Accessed September 27, 2023 at: https://www.afro.who.int/countries/equatorial-guinea/news/equatorial-guinea-confirms-first-ever-marburg-virus-disease-outbreak
• 10 International Society for infectious diseases (1.3.2023). Accessed September 27, 2023 at: https://promedmail.org/promed-post?place=8708654,68892
• 11 Callaway E. Marburg virus outbreak: researchers race to test vaccines. Nature 2023; 614: 603. . DOI: 10.1038/d41586-023-00468-5. (PMID: 36792905)
• 12 Hamer MJ, Houser KV, Hofstetter AR. et al. Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial. Lancet 2023; 401: 294-302 DOI: 10.1016/S0140-6736(22)02400-X. (PMID: 36709074)
• 13 Hunegnaw R, Honko A, Wang L. et al. Rapid and durable protection against Marburg virus with a single-shot ChAd3-MARV GP vaccine. bioRxiv 2021; DOI: 10.1101/2021.12.22.472410.
• 14 Jones SM, Feldmann H, Stroher U. et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005; 11: 786-790 DOI: 10.1038/nm1258. (PMID: 15937495)
• 15 Daddario-DiCaprio KM, Geisbert TW, Stroher U. et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 2006; 367: 1399-1404
• 16 Bockstal V, Shukarev G, McLean C. et al. First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study. PLOS ONE 2022; DOI: 10.1371/journal.pone.0274906.
• 17 Radohitzky SR, Iversen P, Lu X. et al. Expanded profiling of Remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro. Sci Rep 2023; 13: 3131 DOI: 10.1038/s41598-023-29517-9.
• 18 Cross RW, Bornholdt ZA, Prasad AN. et al. Combination therapy protects macaques against advanced Marburg virus disease. Nat Commun 2021; 12: 1891 DOI: 10.1038/s41467-021-22132-0. (PMID: 33767178)
• 19 Rigby I, Michelen M, Dagens A. et al. Standard of care for viral haemorrhagic fevers (VHFs): a systematic review of clinical management guidelines for high-priority VHFs. Lancet Inf Dis 2023; DOI: 10.1016/S1473-3099(22)00874-X.